Outcomes of treatment pathways in outpatient treatment of low risk febrile neutropenic cancer patients

Supportive Care in Cancer

Volumn 12, Issue 9, 2004, Pages 657-662

  Escalante, Carmen P ^a   Weiser, Mary Ann ^a   Manzullo, Ellen ^a   Benjamin, Robert ^a   Rivera, Edgardo ^a   Lam, Tony ^a   Ho, Vi ^a   Valdres, Rosalie ^a   Lee, Eva Lu ^a   Badrina, Noemi ^a   Fernandez, Sally ^a   DeJesus, Yvette ^a   Rolston, Kenneth ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Febrile neutropenia; Low risk; Outcomes; Outpatient treatment

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CEFTAZIDIME; CIPROFLOXACIN; CLINDAMYCIN;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; DRUG RESPONSE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; LEUKOCYTE COUNT; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MUCOSA INFLAMMATION; NEUTROPHIL; OUTPATIENT CARE; PATIENT CARE; PATIENT COMPLIANCE; PERFORMANCE; PREDICTION; PRIORITY JOURNAL; RISK FACTOR; SCORING SYSTEM; SOLID TUMOR; STANDARD; TREATMENT FAILURE; ZUBROD SCORE;

ADOLESCENT; ADULT; AGED; AMBULATORY CARE; AMPICILLIN; ANTI-BACTERIAL AGENTS; CANCER CARE FACILITIES; CEFTAZIDIME; CIPROFLOXACIN; CLAVULANIC ACID; CLINDAMYCIN; CRITICAL PATHWAYS; DRUG THERAPY, COMBINATION; FEMALE; FEVER; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; RISK FACTORS; TREATMENT OUTCOME;

EID: 4644299131     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-004-0613-6     Document Type: Article

References (21)

1. Bodey GP, Buckley M, Sathe YS, et al (1966) Quantitative relationships between circulating leukocytes and infections in patients with acute leukemia. Ann Intern Med 64:328-339
2. Bodey GP, Elting LS, Narro J, et al (1993) An open trial of cefoperazone plus sulbactam for the treatment of fever in cancer patients. J Antimicrob Chemother 32:141-152
3. Bodey GP, Fainstein V, Elting LS, et al (1990) B-Lactam regimens for the febrile neutropenic patient. Cancer 65:9-16
4. Bodey G, Reuben A, Elting L, et al (1991) Comparison of two schedules of cefoperazone plus aztreonam in the treatment of neutropenic patients with fever. Eur J Clin Microbiol Infect Dis 10:551-558
5. Calandra T, Zinner Sh, Vixcoli C, et al (1993) Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med 119:584-593
6. Del Prete SA, Ryan SP, Jacobson JS, et al (1999) Safety and costs of treating neutropenic fever in an outpatient setting. Conn Med 63(12):713-717
7. Gilbert C, Meisenberg B, Vredenburgh J, et al (1994) Sequential prophylactic oral and empiric once-daily parenteral antibiotics for neutropenia and fever after high-dose chemotherapy and autologous bone marrow support. J Clin Oncol 12:1005-1011
8. Hidalgo M, Homedo J. Lumbreras C, et al (1999) Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: a prospective, randomized clinical trial. Cancer 85(1):213-219
9. Malik IA, Khan WA, Aziz Z, et al (1994) Self-administered antibiotic therapy for chemotherapy-induced, low-risk neutropenia in patients with nonhematologic neoplasms. Clin Infect Dis 19:522-527
10. Malik IA, Khan WA, Karim M, et al (1995) Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: results of a prospective randomized trial. Am J Med 98:224-231
11. Mullen CA, Petropoulos D, Roberts WM, et al (1999) Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients. Cancer 86(1):126-134
12. NCCN practice guidelines in oncology, vol 1 (2002) Fever and neutropenia. http://nccn.org/physician_gls/f_guidelines.html. Cited 23 July 2003.
13. Pizzo PA, Hathorn JW, Hiemenz J, et al (1986) A randomized trial comparing ceftazadime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 315:552-558
14. Rolston KVI, Berkey P, Bodey GP, et al (1992) A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Arch Intern Med 152:283-291
15. Rolston KVI, Rubenstein EB, Elting LS, et al (1995) Ambulatory management of febrile episodes in low-risk neutropenic patients. In: Programs and Proceedings of the 35th Interscience Conference on Antimicrobial Agents in Chemotherapy, San Francisco, CA, p.333, abstract no. 2235
16. Rubenstein EB, Rolston K, Benjamin RS, et al (1993) Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer 71:3640-4366
17. Talcott JA, Finberg R, Mayer RJ, et al (1968) The medical course of cancer patients with fever and neutropenia. Arch Intern Med 148:2561-2568
18. Talcott JA, Siegel RD, Finberg R, et al (1992) Risk assessment in cancer patients with fever and neutropenia: A prospective, two-center validation of a prediction rule. J Clin Oncol 10:316-322
19. Walter TH, Armstrong A, Bodey, GP, et al (2002) Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34:730-751
20. Winston DJ, Ho WG, Bruckner DA, et al (1991) Beta-lactam antibiotic therapy in febrile granulocytopenic patients. Ann Intern Med 115:849-859
21. Zubrod CG, Schneiderman M, Frei E, et al (1960) Appraisal of methods for the study of chemotherapy of cancer in man: comparative therapeutic trial of nitrogen mustard and trimethylene thiophosphoramide. J Chronic Dis 11:7